CTLA4 and cancer: Furthermore, in recent years, cancer patients undergoing treatment with anti-CTLA-4 and other immune checkpoint inhibitors (CPI) that block inhibitory molecules and enhance immune activation against tumours, have been found to develop autoimmune and immune-mediated inflammatory diseases19–27.